Relative to strengthening prescription drug affordability and pharmacy benefits manager accountability.
The bill is designed to protect consumers and ensure that they have better access to affordable prescription medications. By prioritizing the lowest net-cost drugs and mandating timely access to pricing lists, SB478 seeks to reduce out-of-pocket expenses for patients. It reinforces the need for pharmacy benefit managers to act in the best interest of enrollees, thereby aligning incentives across various stakeholders in the healthcare system. The introduction of provisions on access to biosimilars and out-of-pocket smoothing further demonstrates the bill’s robust approach to addressing affordability.
Senate Bill 478 aims to improve prescription drug affordability and enhance accountability among pharmacy benefit managers (PBMs) in New Hampshire. The bill introduces significant regulatory measures that focus on increasing transparency around drug pricing, eliminating spread pricing practices, and ensuring that all rebates from manufacturers contribute to lowering drug costs for consumers. Additionally, it establishes strict auditing requirements and prohibits retroactive fees on clean claims, promoting fair practices within the pharmaceutical distribution sector.
General sentiment towards SB478 appears to be supportive among health advocates and consumer protection groups, who argue that it will significantly enhance the affordability and accessibility of medications. However, some stakeholders, particularly those in the pharmaceutical and insurance industries, have expressed concerns about the potential economic implications. The fear is that the bill may disrupt established pricing structures and operational practices, possibly leading to unintended consequences in the broader healthcare market.
Notable points of contention include the provision to cap out-of-pocket costs for insulin and the elimination of spread pricing, which some argue may affect PBMs' operational revenues negatively. The legality of the proposed awareness and reporting requirements, designed to secure transparency for consumers without revealing sensitive competitive data, also raised discussions. These debates highlight the ongoing tension between ensuring consumer protection and maintaining the financial viability of pharmacy benefit managers.